Gilead Sciences (GILD) is due to report earnings Tuesday. Let's review the charts that are looking a little "soft" right now.
More from Investing
There is no way to know how long this theme of strong small-cap speculation and short squeezes will continue, but I have no interest in fighting it.
Here's why you should wait for a dip -- not the vaccine glut -- to start buying.